The state of Colorado currently has 65 active clinical trials seeking participants for Lymphoma research studies. These trials are conducted in various cities, including Denver, Aurora, Colorado Springs and Englewood.
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
NCT05138458
Recruiting
This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2023
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Cell Therapy, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy
Register for Updates
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04756726
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered according to different dosing schedules as a single agent and in combination with dexamethasone.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/13/2023
Locations: Colorado Blood Cancer Institute (Sarah Cannon Research Institute), Denver, Colorado
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's
Register for Updates
Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
NCT05798897
Recruiting
This study is a Phase 1multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory NHL. The dose administered is 200 x 10^6 cells (flat dosing).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/04/2023
Locations: Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado
Conditions: Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma
Register for Updates
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
NCT03061305
Recruiting
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials. The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2023
Locations: SCL Health, Broomfield, Colorado +1 locations
Conditions: Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma
Register for Updates
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
NCT02498951
Recruiting
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to gro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/09/2022
Locations: University of Colorado, Denver, Colorado
Conditions: Central Nervous System B-Cell Non-Hodgkin Lymphoma
Register for Updates